Opinion|Videos|June 24, 2024
Managing Clinical Stability in Adults Spinal Muscular Atrophy Patients
Clinical experts in spinal muscular atrophy (SMA) address the issue of patient disengagement from healthcare services, which can occur due to a perceived lack of disease progression or stabilization, leading to undetected disease advancement and increased risk to patients, and provide recommendations for encouraging patients to re-engage with medical care.
Advertisement
Episodes in this series
- SMA is a disease that can be characterized by prolonged periods of perceived clinical stability, and although this likely does not reflect pathological stability since it feels to the patient as if nothing is happening, it can result in disengagement from healthcare. Is this something that you have encountered in your practice?
- How big is this danger for patients with SMA?
- What suggestions do you have to bring back these patients?
How do you discuss the progressive nature of SMA with your adult patients?
Advertisement
Related to this article
In honor of Muscular Dystrophy Awareness Month, held annually in September, NeurologyLive® looks back at the decade-long expansion of the DMD treatment landscape and the data that supports each approval.
Marketed as Fayuvi, the 1-time AAV9 gene therapy showed sustained cerebrospinal fluid heparan sulfate drops and developmental gains among pediatric patients with mucopolysaccharidosis type IIIA in prior studies.
Amy Waldman, MD, Medical Director of the Leukodystrophy Center at Children's Hospital of Philadelphia, discusses zilganersen's mechanism, safety profile, clinical considerations, and what the first-ever approval for Alexander disease means for the broader leukodystrophy field.
Results recently published from the phase 2 HIMALAYA trial reported that SAR443820 did not slow functional decline, and was associated with more adverse events and treatment discontinuations in patients with ALS.
A new study reported that tremor and myoclonus affected nearly 7 in 10 patients with chronic inflammatory demyelinating polyneuropathy, with immunotherapy and beta-blockers showing potential benefit for symptom improvement.
Robert Bowser, PhD, chief scientific officer at Barrow Neurological Institute, recaps his ALS Nexus presentation on TDP-43 biology, the emerging therapeutic landscape, and how cryptic peptide biomarkers could reshape ALS clinical trial design.
Seven experimental DM1 therapies show promise and pitfalls; see latest trial data, a major phase 3 miss, and key 2026 readouts.
The FDA has approved zilganersen (Zanvastro), the first Alexander disease treatment, giving clinicians a disease-modifying option and a clearer framework for counseling patients across the full age and phenotype spectrum.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
2
Exploring the Unmet Needs in CIDP
3
RIPK1 Inhibitor Fails to Slow Functional Decline in Phase 2 ALS Trial
4
Previewing Advancements in Hypersomnia Diagnosis and Treatment
5